Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

endpoints include duration of response, progression-free survival and overall survival.

Owen A. O'Connor, MD, PhD, Director, Lymphoid Development & Malignancy Program and Chief, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, is the international study chair.

In accordance with the PROPEL study design, in January 2007, the DMC completed an interim analysis of safety data based on the first 10 patients enrolled to the study who completed at least one cycle of treatment with PDX, and recommended that the trial continue per the protocol. Also in accordance with the study design, in September 2007, an interim analysis of patient response and safety data was conducted based on the first 35 patients enrolled to the study who completed at least one cycle of treatment with PDX. The results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, the DMC identified no major safety concerns and recommended that the trial continue per the protocol.

The PROPEL trial is being conducted under an agreement with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process. The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of an NDA, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA. The FDA granted orphan drug designation to PDX for the treatment of T-cell lymphoma in July 2006 and granted fast track designation to PDX for the treatment of patients with T-cell lymphoma in September 2006. In April 2007, the Commission of the European Communities, with a favorable opinion of the Comm
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
(Date:3/27/2015)... Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and ... diagnostic imaging centers in China ... agreement under which Concord Medical Services (International) Pte ... agreed to acquire the Fortis Surgical Hospital from ...
(Date:3/26/2015)... 2015 Huntington Memorial Hospital is the first ... aortic valve replacement (TAVR), a minimally invasive replacement of ... way to replace an aortic valve without a chest ... The procedure is performed by a dedicated ... Alex) Durairaj , MD, interventional cardiologist and Robbin ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... (OTC Bulletin Board: SNDZ ), announced today that ... with key brokers and funds.  The purpose of these meetings ... to facilitate funding for Sunridge to execute its business plan ... for this project," states G. Richard Smith, CEO of Sunridge. ...
... NEW YORK, Aug. 24 Regenicin, ... a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, ... has agreed to join the company,s board of directors. ... efforts of PermaDerm™, Regenicin,s proprietary autologous cultured ...
Cached Medicine Technology:Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors 2
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
(Date:3/27/2015)... March 27, 2015 Bleeding is ... undergoing percutaneous coronary intervention (PCI), resulting in increased ... a “risk-treatment paradox,” in which the highest-risk PCI ... are treated less often with bleeding avoidance strategies ... Luke’s Mid America Heart Institute asked the question ...
(Date:3/27/2015)... 27, 2015 Healthpointe is proud to ... M.D., is now treating knee and hip joint disorders ... , Long Beach, and La Mirada. Dr. Stanley Katz ... and hip joint disorders as well as chronic conditions ... in returning his patients back to their normal lives. ...
(Date:3/27/2015)... York, NY (PRWEB) March 27, 2015 Ticket Down ... in Concert in 2015. After a phenomenal and highly ... show "Nashville" will be going out on tour again in 2015 ... The tour gets underway on April 29th in New York City ... AZ at the Comerica Theatre on May 10th. , Fans of ...
(Date:3/27/2015)... San Jose, CA (PRWEB) March 27, 2015 ... last week’s 2015 GPU technology conference (GTC) , the ... to fight cancer and push the human lifespan well beyond ... Baltimore MD informatics company , is one of 12 ... , While other startups in the GTC Emerging ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... Amanda Gardner HealthDay Reporter , MONDAY, Aug. 23 ... be a breast cancer risk factor, new research suggests it,s ... reporting in the Aug. 24 issue of the Journal ... who drank one alcoholic beverage a day were at higher ...
... protein Hsp90 plays a significant role in the survival of ... Universitaet Muenchen (TUM) uncovered this protein,s mode of operation some ... experts with an unexpected pattern of motion. The results are ... journal PNAS and may help researchers discover specific cancer medication. ...
... be available at local pharmacies and doctor,s offices, and government ... receive it. This year,s vaccine protects against H1N1 and two ... break from past years, when the government focused on vaccinating ... people at high risk. "The message is simple now," ...
... hurricane season gets into full swing, mental health teams ... with possible devastation. Psychologists have analyzed decades of research ... needs of the population affected, specifically those with disabilities ... aftermaths of the Oklahoma City bombing and Hurricane Katrina ...
... needs a new vision for health at the ... CMAJ ( Canadian Medical Association Journal ) ... http://www.cmaj.ca/cgi/doi/10.1503/cmaj.101207 published today. While provinces ... of health services, the federal government has a ...
... , MONDAY, Aug. 23 (HealthDay News) -- What activity involves ... brakes? Maybe you,re stumped because the most of the ... years, but the answer is sledding, and new research shows ... year. "It,s probably not something that,s on everyone,s minds ...
Cached Medicine News:Health News:Alcohol May Raise Risk for Certain Breast Cancers 2Health News:Alcohol May Raise Risk for Certain Breast Cancers 3Health News:Munich researchers demonstrate rocking movement in the anti-stress protein Hsp90 2Health News:Government urges universal flu vaccinations 2Health News:Disasters especially tough on people with disabilities, mental disorders 2Health News:Disasters especially tough on people with disabilities, mental disorders 3Health News:Child Sledding Injuries Number 20,000 a Year 2Health News:Child Sledding Injuries Number 20,000 a Year 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: